Get the Stockscreener App
16.81
2.10%
-0.36
After Hours:
16.50
-0.31
-1.84%
Centessa Pharmaceuticals Plc Adr stock is traded at $16.81, with a volume of 851.17K.
It is down -2.10% in the last 24 hours and up +27.64% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
See More
Previous Close:
$17.17
Open:
$17.06
24h Volume:
851.17K
Relative Volume:
0.92
Market Cap:
$2.25B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-10.78
EPS:
-1.56
Net Cash Flow:
$-160.51M
1W Performance:
+9.09%
1M Performance:
+27.64%
6M Performance:
-0.65%
1Y Performance:
+63.36%
1-Day Range:
$16.67
$17.45
1-Week Range:
$15.05
$17.69
52-Week Range:
$9.10
$19.09
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
16.81 | 2.29B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| May-28-25 | Initiated | Needham | Buy |
| May-08-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
The Future of Centessa Pharmaceuticals plc ADR: Analyzing CNTA - investchronicle.com
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares By Investing.com - Investing.com India
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares - Investing.com
Cerity Partners LLC Invests $471,000 in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
Centessa Pharmaceuticals plc ADR Inc. (CNTA) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Taseko Mines Ltd: Navigating Market Fluctuations with a 1.09B Market Cap - investchronicle.com
Head to Head Analysis: Albany International (NYSE:AIN) versus Unifi (NYSE:UFI) - Defense World
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Buy” by Analysts - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% After Insider Selling - Defense World
Centessa Pharma (CNTA) CBO Weinhoff sells $138k in shares - Investing.com
Centessa Pharma CEO Saha sells $694,826 in shares - Investing.com
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders - MarketScreener
Centessa Pharmaceuticals plc Announces Clearance of Investigational New Drug Application for ORX142 - MarketScreener
SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest - Quantisnow
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet - MSN
Centessa Pharmaceuticals Announces Executive Changes By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals Announces Executive Changes - Investing.com India
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 Net Loss $0.20 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 License and Other Revenue of $15M - marketscreener.com
Is Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) A Suitable Stock For New Investors Today? - Stocksregister
Ratios in Focus: Analyzing Centessa Pharmaceuticals plc ADR (CNTA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Investor’s Delight: Centessa Pharmaceuticals plc ADR (CNTA) Closes Weak at 13.50, Down -1.53 - DWinneX
Was Centessa Pharmaceuticals plc ADR (CNTA)’s session last reading good? - uspostnews.com
Top investors say Centessa Pharmaceuticals plc ADR (CNTA) ticks everything they need - Sete News
Investor’s Toolkit: Key Ratios for Assessing MSCI Inc (MSCI)’s Performance - DWinneX
Financial Metrics Check: Centessa Pharmaceuticals plc ADR (CNTA)’s Ratios for Trailing Twelve Months - DWinneX
Should investors be concerned about Centessa Pharmaceuticals plc ADR (CNTA)? - uspostnews.com
Parsons Corp (PSN) Shares Up Despite Recent Market Volatility - News Heater
Lantheus Holdings Inc [LNTH] Insider Activity: An Update for Investors - knoxdaily.com
Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target - MarketScreener
Centessa Pharmaceuticals chief business officer sells $163,386 in stock - Investing.com
Centessa Pharmaceuticals CEO sells shares worth $918,060 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CEO sells shares worth $918,060 - Investing.com India
Centessa Pharmaceuticals CAO sells shares worth $120,205 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CAO sells shares worth $120,205 - Investing.com India
Centessa Pharmaceuticals’ general counsel sells $98,697 in stock - Investing.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - Stocks Register
Ratios Revealed: Decoding Centessa Pharmaceuticals plc ADR (CNTA)’s Financial Health - The Dwinnex
Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight - GlobeNewswire Inc.
Centessa Pharmaceuticals officer sells shares worth $588,943 - Investing.com India
Aegon Ltd (AEG) looking to reclaim success with recent performance - SETE News
Adversity is less terrifying than hope: Wayfair Inc (W) - SETE News
Perhaps timely catching Autolus Therapeutics plc ADR (AUTL) would be a good idea - SETE News
Taking the lead: Centessa Pharmaceuticals plc ADR (CNTA) - SETE News
Centessa Pharmaceuticals plc ADR (CNTA) Volatility Hits 6.67%: What Good Investors Need To Be Aware Of - Stocks Register
RLI Corp’s (RLI) Stock: A Week-by-Week Analysis - The News Heater
Centessa Pharmaceuticals plc ADR (CNTA) Shares Up Despite Recent Market Volatility - The News Heater
Aon plc (AON) Stock: Evaluating the Market Performance - The News Heater
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):